Faculty. Disclosures. Learning Objectives. Definitions. Definitions (cont) The Role of the Kidney in Cardiometabolic Disease
|
|
- Bruce Jones
- 6 years ago
- Views:
Transcription
1 Faculty The Role of the Kidney in Cardiometabolic Disease Christian W. Mende, MD, FACP, FACN, FASN, FASH Clinical Professor of Medicine University of California at San Diego San Diego, California Disclosures Learning Objectives Dr. Mende: Scientific Advisor Islet Sciences, Inc.; Speakers Bureau Allergan, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen; Office CSO Islet Sciences, Inc. Analyze each component of cardiometabolic syndrome and the associated risk of CKD Evaluate assessment techniques for CKD risk in patients with cardiometabolic syndrome Examine associated comorbidities in patients with cardiometabolic syndrome Assess pharmacotherapy options and therapeutic goals to treat CKD in patients with cardiometabolic syndrome CKD = chronic kidney disease. Definitions Definitions (cont) CKD (CKD - KDIGO 2013) present 3 months egfr <60 ml/min/1.73 m² or Albuminuria 300 mg or Abnormal histology (biopsy) or transplantation Abnormal structure (polycystic kidney disease) Progression of CKD Loss of GFR >5 ml/y Change of category (ie, from CKD 3 to 4) Loss of >25% GFR from baseline Kidney Disease: Improving Global Outcomes; egfr = estimated glomerular filtration rate; GFR = glomerular filtration rate. KDIGO. Kid Int. 2013;3(1): CMS Large waist circumference: women, 89 cm and above; men, 102 cm and above High triglyceride levels: 150 mg/dl or higher Reduced HDL: <40 mg/dl for men, <50 mg/dl for women Increased blood pressure: 130/80 mm Hg or higher Elevated fasting blood glucose: 100 mg/dl or higher CMS = cardiometabolic syndrome; HDL = high-density lipoprotein. KDIGO = Kidney Disease Improving Global Outcomes; egfr = epidermal growth factor receptor. KDIGO. Kid Int. 2013;3(1): Mayo Clinic Medical Staff Publication [online], March 19,
2 ARIC study Risk of CKD in CMS 10,096 non-diabetic participants with no CKD 21% had CMS (ATP III), followed for 9 years CKD developed in 7% NHANES III (2004) 2.6-fold greater incidence with CMS vs general population Spanish study 1498 patients with CMS with 3 components 6.7-fold greater incidence of CKD CKD Need to differentiate between new-onset CKD vs the progression of CKD Normal loss of egfr (after age 40 years) ~ ml/y Type 2 diabetes mellitus >2 ml/y CMS (no data) likely >1.0 ml/y ARIC = Atherosclerosis Risk in Communities; ATP III = Third Adult Treatment Panel; NHANES III = Third National Health and Nutrition Examination Survey Kurella M, et al. J Am J Soc Nephrol. 2005;16: Chen J, et al. Ann Intern Med. 2004;140: Landecho MF, et al. Rev Esp Cardiol. 2011;64(5): Weir MR. Postgrad Med. 2016;128:290,298. Patient #1 A 55-year-old woman with egfr of 90 ml/min ACR 60 (normal <30) BMI 32 (weight, 188 lb; 5 11 ) BP 145/85 mm Hg (no therapy) FBS 110 mg%, TG 220 mg%, LDL 110, HDL 42 Question What are her risk factors for CKD? ACR = albumin-to-creatinine ratio; BMI = body mass index; BP = blood pressure; FBS = fasting blood sugar; TG = triglyceride; LDL = low-density lipoprotein; HDL = high-density lipoprotein. Kidney International Supplements. 2013;3(1): Patient #2 A 61-year-old man with egfr of 45 ml/min (CKD stage 3A) BMI 34 kg/m 2 (220 lb, 5 10 ) BP 155/95 on benazepril 40 mg, HCTZ 25 mg FBS 115 mg%, HDL 32, LDL 110, TG 300 Urine Benign sediment ACR 400 mg/g Note: A 5-mL egfr loss in the past 12 months! Questions What tests are needed to evaluate his renal function? What therapies should be started to slow the progression of CKD? HCTZ = hydrochlorothiazide. Mechanisms Contributing to CKD Risk in CMS Insulin resistance (salt sensitivity, water retention) Increased BP and intraglomerular pressure (mean arterial) Upregulation of multiple systems RAAS (angiotensin-ii, aldosterone) Sympathetic nervous system (leptin) Inflammatory cytokines (macrophages invade fat cells and produce multiple cytokines) IL-6 (elevated hcrp),tnf-alpha, PAI-1,TGF-beta ROS RAAS = renin-angiotensin-aldosterone system; ROS = reactive oxygen species; IL-6 = interleukin-6; hcrp = human C-reactive protein; TNF = tumor necrosis factor; PAI-1 = plasminogen activator inhibitor-1; TGF = transforming growth factor-beta. Schelling JR, et al. J Am Soc Nephrol. 2004;15: Lastra G, et al. Curr Diab Rep. 2006;6: Kurella M, et al. J Am Soc Nephrol. 2005;16: Landecho MF, et al. Rev Esp Cardiol. 2011;64(5): CKD in CMS No data on DIRECT effect of CMS, per se, causing CKD One needs to analyze EACH component of CMS for its risk of CKD Insulin resistance is not unique in CMS, but seen in many conditions Hypertension: ~50% of patients Obesity Pre-diabetes mellitus Type 1 diabetes mellitus: ~50% Type 2 diabetes mellitus: ~90% Polycystic ovary syndrome Lectures from Drs. DeFronzo, Raven, et al. World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Los Angeles, CA. 2
3 Hypertension as a CKD Risk in CMS Microalbuminuria CKD risk of systolic BP >140 mm Hg 2.5 times greater than normotension Mechanisms Upregulation of RAAS and SNS Albuminuria Increased intraglomerular pressure Microvascular injury Renal artery stenosis (bilateral/high grade) Microalbuminuria is NOT a sign of renal disease/ckd, but represents the following: Endothelial dysfunction with its risks for cardiovascular events and mortality Risk of progression of micro-albuminuria to albuminuria SNS = sympathetic nervous system. Schelling JR, et al. J Am Soc Nephrol. 2004;15: Lastra G, et al. Curr Diab Rep. 2006;6: Kurella M, et al. J Am Soc Nephrol. 2005;16: Landecho MF, et al. Rev Esp Cardiol. 2011;64(5): Bakris GL, et al. Diabetes Care. 2014;37(3): Blood Pressure in CKD/CMS CKD Blood Pressure Guidelines Blood pressure control is the most effective intervention in CKD NO albuminuria: BP <140/90 mm Hg Albuminuria (>30 mg/d) BP <130/80 mm Hg Use ACEIs or ARBs if >30 mg/d albuminuria Lifestyle BMI >20-25 kg/m 2 Salt <6 g (2400 mg Na) Exercise 30 minutes 5x/week Couser WG, et al. Kidney Int. 2011;80(12): ACEI = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index. Kidney International Supplements. 2013;3(1): Drug Choices for Hypertension in Patients with CKD with CMS RAAS blockade: ACEI or ARB Diuretics: Chlorthalidone preferred over HCTZ Effective to egfr of 30 ml/min Longer duration of action SBP decline of ~7 mm Hg more For egfr <30 ml = need for loop diuretics CCB Aldactone (if egfr >30), observe K! Alpha and beta blockers SBP = systolic blood pressure; CCB = calcium channel blocker; K = potassium. KDIGO Clinical Practice Guidelines for the Management of Blood Pressure in Chronic Kidney Disease. December 2012;2(5). Bed-Time Dosing in Patients with Diabetes Mellitus or CKD (at Least 1 BP Drug at Bedtime) Diabetes mellitus ABPM 48 hours: HTN present, if BP 135/85 or nocturnal BP >120/ patients taking 3 drugs ONE hypertension medication at bedtime follow-up: 5.4 years Each 5-mm Hg nocturnal SBP decline = 12% decline of CV events (CVA, MI, CV death) CKD 695 patients with egfr <60, 7-year follow-up (ABPM 48 hours) ONE hypertension medication at bedtime Each 5-mm Hg nocturnal SBP decline = 14% decline of CV events ABPM = ambulatory blood pressure monitoring; MI = myocardial infarction. Hermida RC, et al. Diabetes Care. 2011;134: J Am Soc Nephrol. 2011;22:
4 Issues Use of Beta Blockers for Hypertension in CMS Weight gain Increased resistance to insulin Risk of development of diabetes mellitus Only non-vasodilating beta blocker approved for post-mi in hypertension Vasodilating beta blocker preferred Patients taking carvedilol or nebivolol have little risk of developing diabetes mellitus and fewer adverse effects Obesity as a CKD Risk in CMS Renal effects of obesity Hormonal: Activation of RAAS angiotensin-ii, aldosterone SNS, leptin, ROS Physical: Compression of renal parenchyma Structural: Glomerulopathy (focal glomerulosclerosis), glomerulomegaly albuminuria Functional: Elevated egfr Afferent vasodilation + efferent vasoconstriction = hyperfiltration Manrique C, et al. J Clin Hypertens (Greenwich). 2009;11(6): Frishman WH, et al. J Clin Hypertens (Greenwich). 2011;13(9): Ayers K, et al. Hypertension. 2012;59: Cockcroft JF, et al. J Clin Hyperts (Greenwich). 2012;l14(2): Locatelli F, et al. J Am Soc Nephrol. 2006;17:S81-S85. Schelling JR, et al. J Am Soc Nephrol. 2004;15: Thomas G, et al. Clin J Am Soc Nephrol. 2011;6(10): Obesity and CKD Obesity and CKD Risk Obesity is an INDEPENDENT risk factor for CKD CKD RR 1.83 (female > male) Progression of CKD Focal and segmental glomerulosclerosis Micro-albuminuria and macro-albuminuria ESRD (risk for BMI >30 kg/m 2 x 3, BMI >36 kg/m 2 x5) Renal calculi Renal cell carcinoma Obesity = 2.5 times CKD risk Obesity is associated with the following: Albuminuria Insulin resistance Increased RAAS and SNS activation Inflammatory state Hypertension (80%) and risk of increasing BP RR = relative risk. Hsu CY, et al. Ann Intern Med. 2006;144(1): Thomas G, et al. Clin J Am Soc Nephrol. 2011;6(10: Obesity and CKD CKD Risk in MHO Veteran s Administration study of 3,376,187 US veterans with egfr >60 ml/min Mean age, 60 years BMI, ~29 kg/m 2 Followed for 7 years Results 8.1% (274,764) aged >40 years and BMI >30 kg/m 2 developed progressive egfr loss of >5 ml/min/y Best outcome: BMI >25 kg/m 2 but <30 kg/m Korean patients with BMI 26, ~age 67 years No insulin resistance, dyslipidemia, or hypertension (with egfr >60 ml) compared to non-obese MHO BMI 22 kg/m 2 in a 3-year study ~40% greater CKD risk (egfr <60 ml) HR, 1.38 (CI, ) Lu JL, et al. Lancet Diabetes Endocrinol. 2015;3(9): MHO = metabolically healthy obese; HR = hazard ratio; CI = confidence interval. Jung CH, et al. Kidney Int. 2015;88(4):
5 Hyperglycemia as a CKD Risk in CMS There are NO trials to assess the risk of hyperglycemia, per se, as a CKD risk All trials for CKD and CKD progression are in NON-diabetic patients Sparse data in diabetes mellitus without other comorbidities point to 20 years duration before the development of CKD In CMS, hyperglycemia is often not severe enough to be a renal factor Hyperglycemia and Microalbuminuria/Macroalbuminuria Multiple trials in diabetes mellitus show a reduction in new-onset microalbuminuria/macroalbuminuria with stringent A1C control DCCT (type 1 diabetes mellitus A1C 7.3 vs 9.1) reduction new-onset microalbuminuria 39% and macroalbuminuria 54% UKPDS (newly diagnosed type 2 diabetes mellitus) 10-year follow-up: Risk reduction for microalbuminuria 33% in intensive group (A1C difference 11% between groups) ACCORD intensive A1C group to < followed for 6.5 had reduced ESRD (number needed to treat = 410) but higher mortality (any benefit?) Bakris GL. Lecture at the International Society of Nephrology Meeting. Cape Town, South Africa, Bakris GL. May Clin Proc. 2011;86(5): Bloomgarden ZT. Diabetes Care. 2009;32(6):e64-e68. Abdelhafiz AH, et al. Aging Dis. 2015;6(4): Perkovic V, et al. Kidney Int. 2013;83(3): Zoungas S, et al. N Engl J Med. 2014;371: Hyperglycemia and Microalbuminuria/Macroalbuminuria (cont) Multiple trials in diabetes mellitus show a reduction in new-onset microalbuminuria/macroalbuminuria with stringent A1C control (cont) ADVANCE (5.4 years of A1C <6.5% vs 7.1%) reduced new-onset microalbuminuria by 9% and macroalbuminuria by 33% ADVANCE ON (followed post-trial 6 more years with same A1CE) showed reduction of ESRD (HR.54) with 29 vs 53 There are no data on hyperglycemia in CMS and effect on microalbuminuria/macroalbuminuria or new-onset of CKD or CKD progression Hyperlipidemia as a CKD Risk in CMS No trials or data exist on the effect of hyperlipidemia as a risk factor for CKD Small studies show a benefit in slowing progression of CKD of 1.9 ml/y (same as RAAS blockade) Recent meta-analysis of 57 trials and 140,000 patients with CKD showed a statin therapy benefit of Reduced egfr decline of 0.4 ml/y Mild reduction of albuminuria The main benefit for therapy of hyperlipidemia in CMS is to prevent cardiovascular events Bakris GL. May Clin Proc. 2011;86(5): Bloomgarden ZT. Diabetes Care. 2009;32(6):e64-e68. Abdelhafiz AH, et al. Aging Dis. 2015;6(4): Perkovic V, et al. Kidney Int. 2013;83(3): Zoungas S, et al. N Engl J Med. 2014;371: Fried L, et al. Kidney Int. 2001;59: Su X, et al. Am J Kidney Dis. 2016;67(6): Hyperuricemia and Diabetes Mellitus Nephrolithiasis in CMS 1449 patients with type 2 diabetes mellitus egfr >60 ml/min/1.73 m 2, no albuminuria, divided into uric acid <7.0 and >7.0 mg% followed for 5 years with no therapy for uric acid CKD (egfr <60) developed in 29.5% with uric acid >7.0 mg% 11.4% with uric acid <7.0 mg% The risk of renal calculi formation in CMS is 2x greater than in the general population Predisposing factors Lower urine PH Decreased citrate levels Increased uric acid excretion Increased calciuria (ie, high salt intake) Zoppini G, et al. Diabetes Care. 2012;35: Jeong IG, et al. Am J Kidney Dis. 2011;58(3): West B, et al. Am J Kidney Dis. 2008;51(5):
6 Patient #1 Patient #1 (cont) A 55-year-old woman with an egfr of 90 ml/min ACR 60 (normal <30) BMI 32 (weight, 188 lb; 5 11 ) BP 145/85 mm Hg (no therapy) FBS 110 mg%, TG 220 mg%, LDL 110, HDL 42 What are her risk factors for CKD? Age: Loss of egfr of ~1 ml/y after age 40 years Progression of MICRO to MACRO albuminuria (ie, ACR >300 mg/g) Obesity Cardiovascular events (MI, congestive heart failure) affecting renal function Patient #2 A 61-year-old man with egfr of 45 ml/min (CKD 3a) BMI 34 (220 lb, 5 10 ) BP 155/95 taking benazepril 40 mg, HCTZ 25 mg FBS 115 mg%, HDL 32, LDL 110, TG 300 Urine Benign sediment ACR 400 mg/g Note: A 5-mL egfr loss in the past 12 months! Questions What tests are needed to evaluate his renal function? What therapies should be started to slow the progression of CKD? Patient #2 (cont) What tests and therapy are needed to slow progression of his CKD? Renal ultrasound, A1C, calcium, phosphates, parathyroid hormone, vitamin D, electrolytes, sodium bicarbonate, uric acid Lower SBP <130 mm Hg Change hydrochlorothiazide to chlorthalidone Add calcium channel blocker Consider spironolactone mg or eplenerone mg Observe potassium levels Lower LDL to <70 mg/dl Weight loss of at least 10 lbs What s the Take Home? The risk of CKD in CMS is 2.5 times greater than in the general population Hypertension (uncontrolled) and obesity are the two major risk factors of CKD in CMS Avoid non-vasodilating beta blockers in CMS to treat hypertension (unless post-mi) Use bedtime dosing of at least one drug for hypertension in CMS Questions? 6
Metabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationMetabolic Consequences of Anti Hypertensives: Is It Clinically Important?
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationOutpatient Management of Chronic Kidney Disease for the Internist
Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationCONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL
CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL Douglas G. Kelling Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised, April 8, 2012 The information contained in this protocol
More informationDiabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationDiabetes and the heart: mechanisms of cardiac injury, hypertension and heart failure. SAGLB.DIA u Date of approval: November 2017
Diabetes and the heart: mechanisms of cardiac injury, hypertension and heart failure SAGLB.DIA.17.08.0968u Date of approval: November 2017 Abbreviations ACS: acute coronary syndrome AGE: advanced glycoxidation
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCLINICIAN INTERVIEW A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY. Interview with Ralph Rabkin, MD
A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY Interview with Ralph Rabkin, MD Dr Rabkin is Professor of Medicine, Emeritus, Active, at Stanford University School of Medicine, Stanford,
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationHypertension Management in Diabetic Patients
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
More informationHypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease
Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease July 2017 Indranil Dasgupta DM FRCP, Debasish Banerjee MD
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More information